Abstract

Age-associated cognitive-decline is a risk factor for Alzheimer’s disease (AD), but mechanisms are not well understood, and interventions are lacking. Rodent studies on AD have not led to therapeutic breakthroughs for cognitively-impaired humans. In an open-label trial in older-adults we found that supplementing GlyNAC (glutathione precursors glycine and N-acetylcysteine) improved cognitive-decline, defects in whole-body mitochondrial-function, and systemic insulin-resistance, oxidative-stress, and inflammation. We hypothesized that aged-mice will have similar defects in the brain, and studied male C57BL/6J mice as follows: young-mice (20w) were compared to two-groups of aged-mice (90-weeks) receiving either GlyNAC or isonitrogenous-placebo diets for 8-weeks. GlyNAC-supplementation improved cognition, and the following measures in the brain: glutathione-concentrations, glucose-transporters in blood-brain-barrier and neurons, mitochondrial glucose-oxidation, oxidative-stress, endoplasmic-reticulum stress, autophagy, mitophagy, inflammation, senescence, genomic and telomere damage. These data provide mechanistic insights into the novel and beneficial role of GlyNAC supplementation to reverse cognitive-decline in aging, and holds promise for human AD.

Highlights

  • REVERSING COGNITIVE-DECLINE IN OLDER ADULTS IN AN OPEN-LABEL CLINICAL TRIAL: NOVEL MECHANISMS AND THE ROLE OF GLYNAC Chun Liu, Rajagopal Sekhar, Premranjan Kumar, Charles Minard, and Shaji Chacko, Baylor College of Medicine, Houston, Texas, United States

  • We identified and reported that glutathionedeficiency and oxidative-stress in older-adults occur due to decreased availability of precursor amino-acids glycine and cysteine, and can be corrected with glycine and N-acetylcysteine (GlyNAC)

  • We hypothesized that cognitive decline in older-adults is linked to glutathione-deficiency, mitochondrial-dysfunction, oxidative-stress, insulin-resistance, and inflammation

Read more

Summary

Introduction

REVERSING COGNITIVE-DECLINE IN OLDER ADULTS IN AN OPEN-LABEL CLINICAL TRIAL: NOVEL MECHANISMS AND THE ROLE OF GLYNAC Chun Liu, Rajagopal Sekhar, Premranjan Kumar, Charles Minard, and Shaji Chacko, Baylor College of Medicine, Houston, Texas, United States. We hypothesized that cognitive decline in older-adults is linked to glutathione-deficiency, mitochondrial-dysfunction, oxidative-stress, insulin-resistance, and inflammation.

Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.